NSAIDs: Kidney Perfusion, Fluid Retention, and Risk

Lecture collection · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

NSAID risk is highest when kidney perfusion depends on prostaglandins or interacting drugs reduce autoregulatory reserve.

NSAIDs: Kidney Perfusion, Fluid Retention, and Risk. Full text follows below.
Download infographic (PNG) · Download Markdown · Read text version ·

Text version

Why dehydration amplifies risk

Renal prostaglandins support afferent dilation when perfusion is low. NSAID blockade removes that compensation. Vomiting, diarrhea, diuresis, heart failure, or cirrhosis can make kidney function more dependent on this pathway.

Recognize the three-drug combination

ACE inhibitor/ARB reduces efferent tone, a diuretic can reduce circulating volume, and an NSAID limits afferent dilation. Ask specifically about ibuprofen, naproxen, and combination cold or pain products; OTC use may be absent from the medication list.

Distinguish the injury pattern

A rapid creatinine rise during dehydration suggests hemodynamic AKI. New edema, higher BP, and hyperkalemia reflect sodium retention and altered excretion. Proteinuria or persistent dysfunction after withdrawal raises concern for an additional lesion, including AIN.

Choose the analgesic strategy

Identify inflammatory, neuropathic, or mechanical pain first. Use physical measures or a suitable alternative when possible. If an NSAID is necessary, choose the lowest effective exposure and shortest course after reviewing CKD, heart failure, bleeding risk, and interacting medicines.

Make follow-up explicit

For a vulnerable patient, obtain baseline BP, creatinine, and potassium and arrange an early recheck tied to the planned course. New oliguria, vomiting, breathlessness, swelling, or dizziness requires prompt reassessment and no further unsupervised NSAID use.

Worked scenario

An older adult taking losartan and a diuretic develops diarrhea and adds ibuprofen. Check volume status and kidney function, stop the NSAID, and address the illness. Topical products usually reduce systemic exposure but are not permission for unlimited application.

Supporting evidence

Continue learning